Improved Stabilization and Reduction of Particulate Formation in Protein Drug Formulations Using Recombinant Human Albumin (rAlbumin Human USP-NF)

Derived from our proprietary S. cerevisiae yeast expression technology Recombumin Alpha USP-NF* has been developed to deliver quality and unprecedented performance benefits in our customers' applications including drug and vaccine manufacture, device coating, IVF media, specialized cell culture and cell therapy applications. Benefits: Animal-free Secure supply in large volume quantities cGMP for regulatory-compliance and consistency Exceptional purity profile Consistent quality for reduced lot testing or vendor auditing Convenient liquid format Applications: Drug manufacturing - Half-life extension of peptides - Drug targeting and delivery - Albumin micro- and nanoparticle-based drugs. Medical devices - Coating - IVF and advanced cell therapy media ingredient. Cell culture - Stem and therapeutic cell culture - Industrial mammalian cell culture

Recombinant albumin developed as an excipient for use in drug delivery and formulation. Recombumin Prime is the world's first and only supply of commercial, animal-free, recombinant human albumin, approved for use in the manufacture of human therapeutics.Used in the manufacture of the FDA and EMEA approved MMR™ II childhood vaccine from Merck and Co., Recombumin Prime USP-NF* is also being evaluated as an excipient, or ingredient, in several other products undergoing clinical development in the US and EU. Benefits: Stabilize your product in liquid formulation at room temperature Improve visual appearance of lyophilized product and decrease dissolving time Manufactured to Q7 cGMP in FDA, Health Canada and MHRA inspected facilities Extend product bioavailability Half-life extension of peptides. Applications: Protein and peptide drug formulation Vaccine formulation Drug manufacturing ingredient Drug targeting and delivery